Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.

Journal Article (Clinical Trial;Journal Article)

BACKGROUND: Escherichia coli asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia (ALL); however, hypersensitivity develops in up to 30% of patients. We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase, an alternative preparation, in E. coli asparaginase-allergic patients. PATIENTS AND METHODS: Between 2000 and 2002, 215 children with newly diagnosed ALL were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 and were to receive 30 weekly doses of intramuscular E. coli asparaginase. If E. coli asparaginase allergy developed, patients were switched to twice-weekly intramuscular Erwinia asparaginase (25,000 IU/m(2)). Nadir serum asparaginase activity (NSAA) was measured every 3 weeks. RESULTS: Forty-two patients (20%) developed E. coli asparaginase allergy and switched to Erwinia. Of 38 patients with evaluable samples, 34 (89%) Erwinia-treated patients had at least one therapeutic NSAA (> or =0.1 IU/ml). The median NSAA was 0.247 IU/ml 3 days and 0.077 IU/ml 4 days after an Erwinia dose. Associated toxicities included allergy in 14 (33%) and pancreatitis in 3 patients (7%). At a median follow-up of 5.4 years, event-free survival (+/-standard error) of the 42 patients who switched to Erwinia was 86 +/- 5% compared with 81 +/- 3% for the 170 patients without E. coli asparaginase allergy (P = 0.55). CONCLUSIONS: Twice-weekly Erwinia asparaginase was well tolerated and achieved a therapeutically effective NSAA in most E. coli asparaginase-allergic patients. Development of E. coli allergy and subsequent treatment with twice-weekly Erwinia did not adversely impact event-free survival. Erwinia asparaginase should be considered for E. coli asparaginase-allergic patients.

Full Text

Duke Authors

Cited Authors

  • Vrooman, LM; Supko, JG; Neuberg, DS; Asselin, BL; Athale, UH; Clavell, L; Kelly, KM; Laverdière, C; Michon, B; Schorin, M; Cohen, HJ; Sallan, SE; Silverman, LB

Published Date

  • February 2010

Published In

Volume / Issue

  • 54 / 2

Start / End Page

  • 199 - 205

PubMed ID

  • 19672973

Pubmed Central ID

  • PMC3706086

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.22225


  • eng

Conference Location

  • United States